Polyphase wireless power transfer system achieves 270-kilowatt charge, s...
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.
Pengfei Cao, a polymer chemist at ORNL, has been chosen to receive a 2021 Young Investigator Award from the Polymeric Materials: Science and Engineering Division of the American Chemical Society, or ACS PMSE.
Oak Ridge National Laboratory researchers have developed a new catalyst for converting ethanol into C3+ olefins – the chemical
An Oak Ridge National Laboratory researcher has invented a version of an isotope-separating device that can withstand extreme environments, including radiation and chemical solvents.
ASM International recently elected three researchers from ORNL as 2021 fellows. Selected were Beth Armstrong and Govindarajan Muralidharan, both from ORNL’s Material Sciences and Technology Division, and Andrew Payzant from the Neutron Scattering Division.
Scientists at ORNL and the University of Tennessee, Knoxville, have found a way to simultaneously increase the strength and ductility of an alloy by introducing tiny precipitates into its matrix and tuning their size and spacing.
Researchers from NASA’s Jet Propulsion Laboratory and Oak Ridge National Laboratory successfully created amorphous ice, similar to ice in interstellar space and on icy worlds in our solar system. They documented that its disordered atomic behavior is unlike any ice on Earth.
The Department of Energy’s Office of Science has selected five Oak Ridge National Laboratory scientists for Early Career Research Program awards.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.